24/7 Market News Snapshot 15 October, 2024 – Gain Therapeutics, Inc. Common Stock (NASDAQ:GANX)

October 15, 2024

DENVER, Colo., 15 October, 2024 (247marketnews.com) – (NASDAQ:GANX) are discussed in this article.
Gain Therapeutics, Inc. has emerged as a noteworthy player in the biopharmaceutical space, experiencing significant market activity recently. The company’s stock opened today at $2.35 and has shown an impressive bullish momentum, currently trading at $2.585 with a notable 10% increase. This surge is supported by strong investor interest, as evidenced by a trading volume of 673.53K shares. Market analysts indicate that while short-term resistance may surface around $2.60, support seems firmly positioned at $2.35, suggesting that traders should monitor volume fluctuations and potential breakout patterns to evaluate the sustainability of this upward trajectory.

In parallel to its stock market performance, Gain Therapeutics is preparing to showcase its advancements in cancer therapy at the upcoming 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, set to occur from October 23-25, 2024. The company will present a poster detailing the discovery of novel allosteric discoidin domain receptor 2 (DDR2) inhibitors developed through its innovative Magellan platform.

DDR2 is known for its role in tumor progression and is implicated in various cancer types, influencing processes crucial to tumor growth and metastasis. Gain’s allosteric small molecule inhibitors represent a new approach, offering potential advantages in selectivity and safety compared to conventional therapies. The presentation, titled “Identification of Allosteric Inhibitors Targeting Discoidin Domain Receptor 2 (DDR2),” aims to shed light on these promising developments and will be led by Dr. Sara Cano-Crespo during a poster session on October 23.

Furthermore, Gain is actively advancing its lead candidate, GT-02287, for Parkinson’s disease, with early-phase studies demonstrating safety and effective target engagement, positioning the company favorably in the development of therapies for complex diseases. As Gain Therapeutics continues to drive forward in drug discovery, it underscores its commitment to addressing significant health challenges with novel therapeutic strategies.

Related news for (GANX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.